Immunotherapy: the next step in the treatment of myeloma.
Palumbo A et al. Lancet Haematol. 2015 Dec;2(12):e504-5. doi: 10.1016/S2352-3026(15)00226-4. Epub 2015 Nov 16.

Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean.
Olivieri A et al. Bone Marrow Transplant. 2015 Dec 21. doi: 10.1038/bmt.2015.317. [Epub ahead of print].

Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC).
Wu X et al. Int J Epidemiol. 2015 Dec 20. pii: dyv317. [Epub ahead of print].

New pharmacotherapy options for multiple myeloma.
Mina R et al. Expert Opin Pharmacother. 2015 Dec 18:1-12. [Epub ahead of print].

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma.
Hsu P et al. Medicine (Baltimore). 2015 Dec;94(50):e2305. doi: 10.1097/MD.0000000000002305.

Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.
Jonsdottir G et al. Haematologica. 2015 Dec 17. pii: haematol.2015.134049. [Epub ahead of print].

How I treat extramedullary myeloma.
Touzeau C et al. Blood. 2015 Dec 17. pii: blood-2015-07-635383. [Epub ahead of print].

Implications from Under-reporting at Lifetime, Death Certificate Notifications and Trace-back on the Recorded Incidence of a “Newly” Established Population-based Cancer Registry.
Holleczek B et al. Methods Inf Med. 2015 Dec 18;55(2). [Epub ahead of print].

B-Cell Disorders and Curcumin.
Golombick T et al. Integr Cancer Ther. 2015 Dec 16. pii: 1534735415622013. [Epub ahead of print].

First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
Kuhr K et al. Eur J Clin Pharmacol. 2015 Dec 16. [Epub ahead of print].

Association between hepatitis B virus infection and risk of multiple myeloma: A systematic review and meta-analysis.
Li Y et al. Intern Med J. 2015 Dec 12. doi: 10.1111/imj.12981. [Epub ahead of print].

Multiple Myeloma Gets Three New Drugs.
[No authors listed]. Cancer Discov. 2015 Dec 9. [Epub ahead of print].

Screening Performance for Frailty Among Older Patients With Cancer: A Cross-Sectional Observational Study of Two Approaches.
Okuyama T et al. J Natl Compr Canc Netw. 2015 Dec;13(12):1525-31.

Risk of lymphoid neoplasms in a Swedish population-based cohort of 337,437 patients undergoing appendectomy.
Mohammadi M et al. Scand J Gastroenterol. 2015 Dec 14:1-7. [Epub ahead of print].

A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Lee C et al. J Med Econ. 2015 Dec 10:1-17. [Epub ahead of print].

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
Bajpai R et al. Oncogene. 2015 Dec 7. doi: 10.1038/onc.2015.464. [Epub ahead of print].

Novel combination approaches for myeloma.
Lonial S et al. Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015(1):286-93. doi: 10.1182/asheducation-2015.1.286.

Maintenance therapy for multiple myeloma in the era of novel agents.
Facon T et al. Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015(1):279-85. doi: 10.1182/asheducation-2015.1.279.

Evolving diagnostic criteria for multiple myeloma.
Rajkumar SV. Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015(1):272-8. doi: 10.1182/asheducation-2015.1.272.

Advanced pharmacy services support multiple myeloma clinic.
Traynor K. Am J Health Syst Pharm. 2015 Dec 15;72(24):2125-32. doi: 10.2146/news150084.

Monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjögren’s syndrome.
Tomi AL et al. Arthritis Rheumatol. 2015 Dec 4. doi: 10.1002/art.39534. [Epub ahead of print].

Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L et al. Expert Rev Hematol. 2015 Dec 3. [Epub ahead of print].

Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ et al. Support Care Cancer. 2015 Dec 3. [Epub ahead of print].